logo

Heron Therapeutics Inc. (HRTX)



Trade HRTX now with
  Date
  Headline
9/16/2020 8:35:58 AM Heron Therapeutics Announces Publication Of Results From EPOCH 2 Follow-On Study
9/8/2020 8:36:26 AM Heron Reports Successful Outcome Of FDA Type A Meeting To Discuss HTX-011 For Management Of Postoperative Pain; Stock Up
7/24/2020 8:32:30 AM Heron Therapeutics Gets Positive CHMP Opinion For ZYNRELEF For The Management Of Postoperative Pain
7/16/2020 8:32:11 AM Heron Therapeutics Begins GUARDS-1 Study, A Phase 2 Clinical Study Evaluating CINVANTI
6/29/2020 8:47:11 AM Heron Therapeutics Gets CRL For HTX-011 For Management Of Postoperative Pain; Stock Plunges
6/4/2020 9:06:22 AM Heron Publishes Results From Study 209, Phase 2b Study Of HTX-011 In Patients Undergoing Total Knee Arthroplasty
5/18/2020 9:09:04 AM Heron Therapeutics Begins Phase 1b/2 Clinical Study Of HTX-034 For Treatment Of Postoperative Pain
3/2/2020 7:33:20 AM Heron Therapeutics Q4 Loss Per Share $0.65 Vs Loss $0.63 Last Year
1/13/2020 8:37:18 AM Heron Therapeutics Q4 Net Product Sales For CINV Franchise Of $34.8 Mln, Up 21% Y-o-Y
12/3/2019 7:34:13 AM Health Canada Grants Priority Review Status For Heron' NDS For HTX-011 For Management Of Postoperative
10/28/2019 8:36:03 AM Heron : FDA Accepts NDA Resubmission For HTX-011 For Management Of Postoperative Pain